Cardiff Oncology (CRDF) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to 0.76.
- Cardiff Oncology's Equity Ratio fell 258.79% to 0.76 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76, marking a year-over-year decrease of 258.79%. This contributed to the annual value of 0.85 for FY2024, which is 9.19% down from last year.
- Cardiff Oncology's Equity Ratio amounted to 0.76 in Q3 2025, which was down 258.79% from 0.77 recorded in Q2 2025.
- Over the past 5 years, Cardiff Oncology's Equity Ratio peaked at 0.97 during Q2 2021, and registered a low of 0.76 during Q3 2025.
- Its 5-year average for Equity Ratio is 0.88, with a median of 0.89 in 2023.
- As far as peak fluctuations go, Cardiff Oncology's Equity Ratio skyrocketed by 8526.68% in 2021, and later plummeted by 1074.94% in 2024.
- Quarter analysis of 5 years shows Cardiff Oncology's Equity Ratio stood at 0.94 in 2021, then decreased by 2.53% to 0.92 in 2022, then dropped by 6.66% to 0.85 in 2023, then fell by 0.09% to 0.85 in 2024, then decreased by 10.37% to 0.76 in 2025.
- Its Equity Ratio was 0.76 in Q3 2025, compared to 0.77 in Q2 2025 and 0.84 in Q1 2025.